Table 1.

Disease-free survival and overall survival rates for phase III adjuvant trials of novel HER2 inhibitors.

Agent/trial	Disease setting	Regimen	N	Follow-up	DFS	OS
Lapatinib
ALTTO	Stage I–III adjuvant therapy	• Lapatinib trastuzumab+	8381	6 years	85% (HR 0.86)	93% (HR 0.86)
Moreno-Aspitia et al. (2017)		• Lapatinib (34 w) → Trastuzumab (12 w)			84% (HR 0.93)	92% (HR 0.88)
Piccart-Gebhart et al. (2016)		• Trastuzumab			82%	91%
		• Lapatinib			82% (HR 1.34)	93% (HR 1.36)
TEACH	Stage I–III delayed adjuvant therapy. Prior trastuzumab unless contraindicated	• Lapatinib	3147	47.4 mo	87% (HR 0.83)	94% (HR 0.99)
Goss et al. (2013)		• Placebo		48.3 mo	83%	94%
Neratinib
ExteNET	Stage I–III delayed adjuvant therapy. Prior trastuzumab	• Neratinib	2840	5 years	90.2% (HR 0.73)*	Not mature
(Martin et al., 2017)		• Placebo			87.7%*
Pertuzumab
APHINITY	Stage II–III adjuvant therapy	• Pertuzumab (plus chemo & trastuzumab)	4805	36 mo	94.1% (HR 0.81)*	97.7% (HR 0.89)
Von Minckwitz et al. (2017)		• Placebo (plus chemo & trastuzumab)			93.2%*	97.7%

Chemo, chemotherapy; DFS, disease-free survival; ET, endocrine therapy; mo, months; OS, overall survival.

^*Invasive DFS.